Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
Can-Fite BioPharma's drug candidate namodenoson met its primary endpoint in a Phase 2a pancreatic cancer trial and demonstrated anti-obesity effects in a peer-reviewed preclinical study published in the International Journal of Obesity.
U.S. Health Secretary Robert F. Kennedy Jr. claimed ketogenic diets can cure schizophrenia, but psychiatry experts say the assertion goes far beyond what current scientific evidence supports.
